Kazia Therapeutics Limited

NasdaqCM:KZIA Stock Report

Market Cap: US$25.1m

Kazia Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

John Friend

Chief executive officer

AU$1.3m

Total compensation

CEO salary percentage64.5%
CEO tenure1.5yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure2.3yrs

Recent management updates

Recent updates

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Jul 06

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Jun 15

Enrollment gets underway in Kazia's mid-stage lymphoma study

Jun 07

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Dec 10

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Dec 09

Kazia stock +22% on positive paxalisib data in glioblastoma

Nov 18

CEO Compensation Analysis

How has John Friend's remuneration changed compared to Kazia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$825k

-AU$27m

Mar 31 2024n/an/a

-AU$21m

Dec 31 2023n/an/a

-AU$16m

Sep 30 2023n/an/a

-AU$18m

Jun 30 2023AU$2mAU$743k

-AU$20m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$25m

Sep 30 2022n/an/a

-AU$25m

Jun 30 2022AU$1mAU$430k

-AU$25m

Compensation vs Market: John's total compensation ($USD832.04K) is about average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Friend (54 yo)

1.5yrs

Tenure

AU$1,279,844

Compensation

Dr. John Edwin Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Me...

Board Members

NamePositionTenureCompensationOwnership
John Friend
CEO, MD & Director1.3yrsAU$1.28mno data
Robert Apple
Non-Executive Directorless than a yearAU$39.30kno data
Bryce Carmine
Independent Non-Executive Chairman9.4yrsAU$95.42kno data
Patrick Wen
Member of Scientific Advisory Board2.3yrsno datano data
Steven Coffey
Independent Non-Executive Director12yrsAU$94.35kno data
Ebru Davidson
Independent Non-Executive Director1.4yrsAU$94.35kno data
Priscilla Brastianos
Member of Scientific Advisory Board2.3yrsno datano data
John de Groot
Member of Scientific Advisory Board2.3yrsno datano data
Alan Olivero
Member of Scientific Advisory Board2.3yrsno datano data

2.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: KZIA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.